Targeting Intermediary Metabolism Enhances The Efficacy Of BH3 Mimetic Therapy In Haematological Malignancies



Al-Zebeeby, Aoula, Vogler, Meike, Milani, Mateus, Richards, Caitlin, Alotibi, Ahoud, Greaves, Georgia, Dyer, Martin JS, Cohen, Gerald M and Varadarajan, Shankar ORCID: 0000-0002-8827-6567
(2019) Targeting Intermediary Metabolism Enhances The Efficacy Of BH3 Mimetic Therapy In Haematological Malignancies. Haematologica: the hematology journal, 104 (5). 1016 - 1025.

This is the latest version of this item.

[img] Text
Author Accepted Version.pdf - Accepted Version

Download (5MB)

Abstract

BH3 mimetics are novel targeted drugs with remarkable specificity, potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to increasing doses of navitoclax (ABT-263), a BH3 mimetic. To mimic such rapid development of chemoresistance, we developed simple resistance models to three different BH3 mimetics, targeting BCL-2 (ABT-199), BCL-X-L (A-1331852) or MCL-1 (A-1210477), in relevant hematologic cancer cell lines. In these models, resistance could not be attributed to either consistent changes in expression levels of the anti-apoptotic proteins or interactions among different pro- and anti-apoptotic BCL-2 family members. Using genetic silencing, pharmacological inhibition and metabolic supplementation, we found that targeting glutamine uptake and its downstream signaling pathways, namely glutaminolysis, reductive carboxylation, lipogenesis, cholesterogenesis and mammalian target of rapamycin signaling resulted in marked sensitization of the chemoresistant cells to BH3 mimetic-mediated apoptosis. Furthermore, our findings highlight the possibility of repurposing widely used drugs, such as statins, to target intermediary metabolism and improve the efficacy of BH3 mimetic therapy.

Item Type: Article
Uncontrolled Keywords: Chronic Myelogenous Leukemia, chronic lymphocytic leukemia, molecular pharmacology
Depositing User: Symplectic Admin
Date Deposited: 07 Jan 2019 10:51
Last Modified: 21 Apr 2021 21:26
DOI: 10.3324/haematol.2018.204701
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3029170

Available Versions of this Item